Mesdopetam (hemitartrate)

Mesdopetam (IRL790) hemitartrate is a dopamine D3 receptor antagonist (Ki=90 nM; IC50=9.8 μM for human recombinant D3 receptor) with psychomotor stabilizing properties. Mesdopetam hemitartrate is used for the research of motor and psychiatric complications in Parkinson disease[1][2].

Product Specifications

CAS Number

[2562346-14-7]

Product Name Alternative

IRL790 (hemitartrate)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/mesdopetam-hemitartrate.html

Purity

99.86

Solubility

DMSO : 20.83 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 100 mg/mL (ultrasonic)

Smiles

OC([C@H](O)[C@@H](O)C(O)=O)=O.CCCNCCOC1=CC(S(C)(=O)=O)=CC(F)=C1

Molecular Formula

C12H18FNO3S.1/2C4H6O6

Molecular Weight

350.39

Precautions

H302, H315, H319, H335

References & Citations

[1]Waters S, et al. Preclinical Pharmacology of [2- (3-Fluoro-5-Methanesulfonyl-phenoxy) Ethyl] (Propyl) amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease. J Pharmacol Exp Ther. 2020;374 (1) :113-125. |[2]Becanovic K, et al. Effects of a Novel Psychomotor Stabilizer, IRL790, on Biochemical Measures of Synaptic Markers and Neurotransmission. J Pharmacol Exp Ther. 2020;374 (1) :126-133.